Drug maker PharmaEssentia Corp (藥華醫藥) yesterday began trading its shares on the smaller Emerging Stock Market and highlighted potential sales of drugs it has in the pipeline.
The company’s shares rose 2.33 percent to NT$210.8 yesterday from the initial public offering price of NT$206, valuing the company at NT$39.57 billion (US$1.31 billion).
The company expects to receive regulatory permission to sell a new drug for treating blood disorders in the US and Europe during the first half of 2016, PharmaEssentia financial director Ellen Chang (張慧敏) said.
The new drug, P1101, is under phase-three clinical trials in Europe, conducted by its European partner AOP Orphan Pharmaceutical AG, Chang said.
PharmaEssentia will soon apply for phase-three trials for the drug in the US and plans to conduct clinical trials for the drug in Taiwan and China in the near future, she said.
Jih Sun Securities Investment Consulting Co (日盛投顧) said PharmaEssentia could acquire 16 percent of P1101 sales from AOP Orphan Pharmaceuticals as royalties after the drug is launched in Europe.
“Currently there is no effective cure for the blood disorder, except P1101 and Jakafi of US-based drug maker Incyte Corp, but because Jakafi is still under phase-two clinical trials and expected to hit the market in 2018, we expect sales of P1101 to benefit from its early entry,” Jih Sun analyst Chang Li-chun (張立群) said in a report yesterday.
Meanwhile, PharmaEssentia is also conducting phase-two trials on the P1101 drug in Taiwan to test whether it can be used to cure hepatitis B and C, and hopes to conduct phase-three studies in South Korea, Thailand and Singapore, according to the company.
However, Jih Sun is less optimistic about sales of the drug for curing hepatitis B and C because the market is already occupied by rival drugs in the US and Europe.
“It is a correct strategy for PharmaEssentia to focus on the Asian market, but the largest market for hepatitis C drugs — China — is a relative closed market,” the analyst said, adding that the company needs to find local partners in China and maybe set up a factory in the country to gain Chinese government approval to sell the drug.
During the first half of last year, the company posted losses of NT$174.7 million, widening from losses of NT$125.89 million a year earlier, because of high research and development expenditure, according to the company’s filing to the Taiwan Stock Exchange.
PharmaEssentia said its research spending this year would be NT$600 million to NT$700 million, slightly higher than last year.
The company is to apply for listing on the GRETAI securities market after six months and it estimates it will be listed on the market in the fourth quarter of this year.
Taiwan Transport and Storage Corp (TTS, 台灣通運倉儲) yesterday unveiled its first electric tractor unit — manufactured by Volvo Trucks — in a ceremony in Taipei, and said the unit would soon be used to transport cement produced by Taiwan Cement Corp (TCC, 台灣水泥). Both TTS and TCC belong to TCC International Holdings Ltd (台泥國際集團). With the electric tractor unit, the Taipei-based cement firm would become the first in Taiwan to use electric vehicles to transport construction materials. TTS chairman Koo Kung-yi (辜公怡), Volvo Trucks vice president of sales and marketing Johan Selven, TCC president Roman Cheng (程耀輝) and Taikoo Motors Group
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
RECORD-BREAKING: TSMC’s net profit last quarter beat market expectations by expanding 8.9% and it was the best first-quarter profit in the chipmaker’s history Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), which counts Nvidia Corp as a key customer, yesterday said that artificial intelligence (AI) server chip revenue is set to more than double this year from last year amid rising demand. The chipmaker expects the growth momentum to continue in the next five years with an annual compound growth rate of 50 percent, TSMC chief executive officer C.C. Wei (魏哲家) told investors yesterday. By 2028, AI chips’ contribution to revenue would climb to about 20 percent from a percentage in the low teens, Wei said. “Almost all the AI innovators are working with TSMC to address the
FUTURE PLANS: Although the electric vehicle market is getting more competitive, Hon Hai would stick to its goal of seizing a 5 percent share globally, Young Liu said Hon Hai Precision Industry Co (鴻海精密), a major iPhone assembler and supplier of artificial intelligence (AI) servers powered by Nvidia Corp’s chips, yesterday said it has introduced a rotating chief executive structure as part of the company’s efforts to cultivate future leaders and to enhance corporate governance. The 50-year-old contract electronics maker reported sizable revenue of NT$6.16 trillion (US$189.67 billion) last year. Hon Hai, also known as Foxconn Technology Group (富士康科技集團), has been under the control of one man almost since its inception. A rotating CEO system is a rarity among Taiwanese businesses. Hon Hai has given leaders of the company’s six